Sponsors (2)
The bill would lower out-of-pocket drug costs for public program enrollees and likely push drug prices down market-wide by tying U.S. prices to international reference prices and reallocating penalties to NIH, but risks industry pushback that could raise list prices or reduce investment in new therapies, while imposing administrative complexity and potential distortions in research funding.
Medicare, Medicaid, CHIP, VA, TRICARE and FEHB enrollees would pay no more than an annual reference price for covered drugs, directly lowering their out-of-pocket prescription costs.
Uninsured and commercially insured patients — and the broader market — would likely face lower drug charges because U.S. prices are anchored to lower prices from a set of developed reference countries, putting downward pressure on list prices and manufacturer charges.
Civil penalties collected for manufacturer noncompliance would be redirected to the NIH, increasing government-supported drug R&D funding without new appropriations.
Drug manufacturers could respond to price limits and steep penalties by raising list prices, delaying or restricting product launches, or reducing R&D investment, which could slow patient access to new therapies and shift costs elsewhere in the system.
The HHS would face substantial administrative and regulatory burden to set annual reference prices and manage cross-country comparisons, risking complexity, delays, and implementation challenges.
Redirecting large penalty revenues to the NIH could create perceptions of punitive funding sources and might skew NIH priorities toward industry-linked R&D at the expense of basic research.
Based on analysis of 2 sections of legislative text.
HHS sets annual international-reference-based drug prices and caps retail list prices for major federal health program enrollees, requiring manufacturers to offer that price to all purchasers.
Official title: To require the Secretary of Health and Human Services to establish reference prices for prescription drugs for purposes of Federal health programs, and for other purposes.
Introduced May 14, 2025 by Debbie Dingell · Last progress May 14, 2025
Requires HHS to set an annual "reference price" for every prescription drug and caps the retail list price charged to enrollees or beneficiaries in major federal health programs at that reference price. Manufacturers must offer drugs at or below the reference price to all purchasers (including uninsured and private plans); large civil penalties (five times excess receipts) apply for noncompliance, with penalty funds directed to NIH for drug research.